CD19 and systemic sclerosis: Furthermore, A study demonstrated the first use of blinatumomab, a bispecific anti-CD3/CD19 antibody, as a B-cell depletion therapy for systemic sclerosis, revealing profound B-cell depletion with no increase in infection risk, along with an improvement in clinical manifestations (47).